Abstract
In western countries, 85% of chronic rhinosinusitis with nasal polyp disease reveals a type 2 inflammatory pattern with expression of IL-4, -5, and -13 as well as increased concentrations of IgE, whereas chronic rhinosinusitis without nasal polyps merely expresses these biomarkers. The degree of type 2 inflammation furthermore is associated with disease severity, asthma comorbidity, and recurrence of disease after surgery. Therefore, these biomarkers also form the targets for innovative therapeutic approaches such as monoclonal antibodies directed against IgE, IL-5, and IL-4 receptor alpha, blocking the activity of IL-4 and -13. Having demonstrated efficacy in severe asthma, the antibodies have been tested in proof-of-concept studies in patients with nasal polyposis with or without asthma, and have demonstrated their potential to reduce nasal and sinus nasal polyp burden monitored by nasal endoscopy and computed tomography scanning, and to improve typical symptoms. No biomarkers have been identified to select subjects for therapy, to predict response to a specific drug, or to monitor treatment success, which is best documented by nasal polyp score and symptoms. Phase 3 studies are currently in preparation or running, which aim ...Continue Reading
Citations
Jan 16, 2018·International Forum of Allergy & Rhinology·Vincent DupuchBertrand Evrard
Jul 20, 2018·American Journal of Rhinology & Allergy·Kristine A SmithJeremiah A Alt
Sep 9, 2018·Expert Review of Respiratory Medicine·Garry M Walsh
Feb 13, 2019·International Forum of Allergy & Rhinology·Nam-Kyung YeoJi Hwan Lee
Nov 23, 2018·European Respiratory Review : an Official Journal of the European Respiratory Society·Angelica TiotiuAndras Bikov
May 11, 2019·Clinical Reviews in Allergy & Immunology·Aarti AgarwalJens U Ponikau
May 15, 2019·Current Opinion in Allergy and Clinical Immunology·Chengshuo Wang, Luo Zhang
Mar 23, 2018·Allergo Journal International·Michael KoenneckeBarbara Wollenberg
Dec 4, 2019·Current Opinion in Otolaryngology & Head and Neck Surgery·Melina S NastaChristos C Georgalas
May 4, 2020·International Forum of Allergy & Rhinology·Devyani LalMatthew A Rank
Jun 23, 2020·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·John W Upham, Lisa M Jurak
May 31, 2018·Current Allergy and Asthma Reports·Jordan HeathJoshua L Kennedy
Jan 27, 2019·Immunotherapy·Garry M Walsh
Aug 28, 2020·Pediatric Investigation·Tan ShineeBaharudin Abdullah
Mar 22, 2019·International Journal of Molecular Sciences·Emilie BequignonValérie Gouilleux-Gruart
Mar 27, 2020·Journal of Translational Medicine·Emilie BequignonAndré Coste
Apr 24, 2020·Current Allergy and Asthma Reports·W Colby Brown, Brent Senior
Sep 1, 2018·HNO·L KlimekS Becker
Sep 19, 2017·Expert Review of Respiratory Medicine·Amelia LicariGian Luigi Marseglia
Oct 19, 2020·The Journal of Allergy and Clinical Immunology. in Practice·Katrien EgerElisabeth H Bel
Feb 13, 2021·The Annals of Otology, Rhinology, and Laryngology·Michael A BelskyStella E Lee
Dec 7, 2018·Current Opinion in Otolaryngology & Head and Neck Surgery·Jonathan YipYvonne Chan
Dec 7, 2018·Current Opinion in Otolaryngology & Head and Neck Surgery·Aryan D Shay, Bobby A Tajudeen
Feb 6, 2021·Revue des maladies respiratoires·S BartierE Bequignon
Nov 21, 2018·The Medical Journal of Australia·John W Upham, Li Ping Chung
Nov 22, 2020·Biomolecules·Yoshimasa ImotoShigeharu Fujieda
Feb 18, 2021·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·Jody TverskyAntoine Azar
Dec 29, 2020·European Annals of Otorhinolaryngology, Head and Neck Diseases·S BartierE Béquignon
Apr 20, 2021·Brazilian Journal of Otorhinolaryngology·Wilma T Anselmo-LimaFabiana C P Valera
Jun 1, 2021·Expert Review of Respiratory Medicine·Maria De FilippoGian Luigi Marseglia
Jun 5, 2021·Cytokine·Jae Woong HwangSang Hag Lee
Oct 26, 2021·Ear, Nose, & Throat Journal·Ruwaa SamarraiKourosh Parham